Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records

Young, Joel L.; Powell, Richard N.; Powell, Anna; Welling, Lisa L. M.; Granata, Lauren; Saal, Jaime; Nash, Margot

doi:10.1186/s12888-024-06446-z

Table 4 Point-biserial Pearson correlations demonstrating the relationship between each continuous variable and the addition of IR medication at 90 days. Treatment responses representing a change in score between baseline and 90 days were Z-transformed prior to analysis

From: Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records

Variable Group	Variable	Description	Pearson correlation coefficient (r)	R²	p
Demographics	Age	Age in Years	0.02	0.00032	0.716
ER Prescription Decision	Tendency to Prescribe ER	Integer Value: % of patients with an ER prescription	− 0.10	0.0090	0.07
ER Prescription Decision	Time in Treatment Prior to ER	Integer Value	− 0.05	0.0023	0.33
Assessment scores at baseline	ASSET	ADHD symptoms in terms of daily life functioning impact at the time of visit	0.050	0.0025	0.31
	PHQ-9	Severity of depressive symptoms in terms of frequency at the time of visit	− 0.03	0.00096	0.53
	GAD-2	Severity of anxious symptoms in terms of frequency at the time of visit	− 0.05	0.0028	0.28
	CGI-S	Global severity of the overall presentation assessed by the clinician at the time of visit	− 0.05	0.0023	0.34
	CGI-I	Global improvement of the overall presentation assessed by the clinician	− 0.14	0.020	0.01
Assessment scores at 90 days^a	ASSET	Severity of ADHD symptoms in terms of daily life functioning impact	− 0.03	0.00063	0.62
	PHQ-9	Severity of depressive symptoms in terms of frequency	− 0.00	0.000004	0.96
	GAD-2	Severity of anxious symptoms in terms of frequency	0.04	0.0013	0.47
	CGI-S	Global severity of the overall presentation assessed by the clinician	− 0.04	0.0014	0.45
	CGI-I	Global improvement of the overall presentation assessed by the clinician	− 0.10	0.0096	0.06
Treatment response (Change in clinical assessments from baseline to 90 days^a)	Change in ASSET	Change of severity of ADHD symptoms in terms of daily life functioning impact	0.09	0.0074	0.08
	Change in PHQ-9	Change of severity of depressive symptoms	− 0.03	0.0011	0.50
	Change in GAD-2	Change of severity of anxiety symptoms	− 0.09	0.0083	0.06
	Change in CGI-S	Change of global severity of the overall presentation assessed by the clinician	− 0.05	0.00086	0.34

ASSET, ADHD Symptom and Side Effect Tracking; CGI-S, Clinical Global Impressions-Severity; CGI-I, Clinical Global Impressions-Improvement; ER, extended release; GAD-2, Generalized Anxiety Disorder 2-Item; PHQ-9, Patient Health Questionnaire-9
^a The visit falling closest to 90 days after ER stimulant was prescribed

Back to article page

ISSN: 1471-244X

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Psychiatry

Contact us